Search

Genmab A-S

Cerrado

2,143 1.71

Resumen

Variación precio

24h

Actual

Mínimo

2091

Máximo

2153

Métricas clave

By Trading Economics

Ingresos

243M

295M

Ventas

259M

1.2B

P/B

Media del Sector

25.63

57.371

BPA

34.85

Margen de beneficios

25.541

Empleados

3,119

EBITDA

216M

431M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-1.49% downside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

18B

131B

Apertura anterior

2141.29

Cierre anterior

2143

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 ago 2026, 23:21 UTC

Bank of Korea Expected to Set Interest Rate at 0.03% Amid Inflation Concerns and Global Economic Influences

24 ago 2026, 23:21 UTC

Canada's Q2 2026 GDP Growth Rate Release Looms Amid Trade Tensions with U.S. Following Unexpected Contraction

24 ago 2026, 23:21 UTC

Canada's July GDP data release on August 28, 2026, expected to show modest growth amid mixed stock sentiment and U.S.-Canada trade tensions.

24 ago 2026, 23:21 UTC

Canada's Q2 2026 GDP Growth Rate Forecasted at 3.4% Amid Cautious Market Sentiment Over U.S.-Canada Trade Tensions

24 ago 2026, 23:16 UTC

Sunrun Inc. shares are higher in after-market hours, though they remain below the 20-day moving average after four consecutive sessions of declines.

24 ago 2026, 23:16 UTC

DHT Holdings Inc shares are higher in after-market trading, with no specific news identified. The U.S. Dollar's strength amid new sanctions may influence oil supply concerns.

24 ago 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

24 ago 2026, 23:16 UTC

News

Trade Desk Inc's stock fell in after-hours trading following a prospectus filing for a mixed shelf offering of various securities. The company holds $1.12 billion in cash.

24 ago 2026, 23:16 UTC

CH Robinson Worldwide Inc. shares are higher in after-market trading, gaining since Monday's close despite routine activity and remaining below its 20-day moving average.

24 ago 2026, 23:16 UTC

Dollar General Corp shares are higher in after-market trading, reflecting routine activity. The stock remains above the 20-day moving average despite earlier fluctuations.

24 ago 2026, 23:16 UTC

Carpenter Technology Corp's shares are lower in after-market hours, with no specific news identified to explain the decline. The price remains below its 20-day moving average.

24 ago 2026, 23:16 UTC

Correlated Moves

PagSeguro Digital Ltd shares are higher in after-market trading, reflecting gains since Monday's close amid a price increase in StoneCo Ltd.

24 ago 2026, 23:16 UTC

Blue Owl Capital Inc shares are lower in after-market hours, continuing a downward trend since Monday's close, despite an earlier rebound.

24 ago 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

24 ago 2026, 23:16 UTC

Correlated Moves

After-market trading for Vanguard Total Bond Market ETF is little changed. Broader market sentiment may influence bond prices amid geopolitical developments.

24 ago 2026, 23:16 UTC

Fox Corp shares are higher in after-hours trading, maintaining a position above the 20-day moving average and near the upper end of the one-month range.

24 ago 2026, 23:16 UTC

Cummins Inc shares are higher in after-market hours, though no specific company news was identified to explain the movement. The stock has shown recent volatility.

24 ago 2026, 23:16 UTC

Innovative Industrial Properties Inc. shares are higher in after-market hours following notable trading activity. The stock remains below its 20-day moving average.

24 ago 2026, 23:16 UTC

Qfin Holdings Inc shares are higher in after-market trading. No specific company news was identified to explain this movement.

24 ago 2026, 23:16 UTC

Vicor Corp shares are higher in after-market hours, following routine trading. The stock remains flat since the prior close and below its 20-day moving average.

24 ago 2026, 23:16 UTC

Shares of Otis Worldwide Corp are lower in after-market hours, following unusual trading activity. The stock is positioned below its 20-day moving average.

24 ago 2026, 23:16 UTC

Invesco DB Agriculture Fund is slightly higher in after-market trading, with no specific news identified to explain its movement. Global equity indices are mixed.

24 ago 2026, 23:16 UTC

Coca-Cola Consolidated Inc is trading lower in after-market hours, reflecting a decline from recent performance amid a strengthening U.S. Dollar.

24 ago 2026, 23:16 UTC

Regal Rexnord Corp shares are higher in after-market trading, reflecting unusual strength despite being below recent averages and last month's close.

24 ago 2026, 23:16 UTC

ETF Constituents
Macro News

The SEC has issued subpoenas to major banks amid trading investigations. In after-market trading, the SPDR S&P Regional Banking ETF is gaining, led by BPOP.

24 ago 2026, 23:16 UTC

Gartner Inc. shares are lower in after-market hours, reflecting a modest decline. The stock remains well above its 20-day moving average despite recent dips.

24 ago 2026, 23:16 UTC

Prospect Capital Corp shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

24 ago 2026, 23:16 UTC

Essex Property Trust Inc. shares are higher in after-market trading, continuing a trend of seven consecutive sessions with higher closes.

24 ago 2026, 23:16 UTC

Scotts Miracle-Gro Co shares are higher in after-market trading, reaching a peak above Monday's close despite remaining below the 20-day moving average.

24 ago 2026, 23:16 UTC

Alvotech SA shares are trading roughly flat in after-market hours. The stock has gained significantly over the past month, remaining above its 20-day moving average.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

3

Comprar

2

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.